Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron

Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron on the development of novel anticancer agents.
According to two separate agreements, Exiris acquires exclusive rights to, and will pursue the development of, antibody therapeutics that were jointly discovered with ISS and Aldevron during the Eurotransbio-funded ColCab project. Aldevron and ISS will both be eligible for royalty payments on any income arising to Exiris from the commercial exploitation of these agents.